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-7 through -2, before 200 cGy TBI. Unmodified G-CSF-mobi- 
lized peripheral blood stem cells (PBSC) from DLA-haploidenti- 
cal donors were infused followed by iunnunosuppression with 
MMF (5-I0 mg/kg BID SQ for 28-101 days) and CSP (3- 
15mg/kg BID PO for 102 days). Two dogs received additional 
weekly methotrexate (0.4 mg/kg IV from days 42 through 105) 
and 2 dogs received escalating dose of donor lymphocyte infusions 
(DLI) fi'om their donors. Results: All dogs achieved prompt ini- 
tial engraftment with donor chimerism of PBMC ranging from 5- 
90% (median; 60%) 3 weeks after transplant. However, of 2l dogs 
evaluable for engraftment, 15 (71%) rejected their donor grafts 
after discontinnation r dose-reduction f MMF/CSP (5-16 weeks 
after transplant). Graft rejections occurred later in dogs given pro- 
longed immnnosuppression when compared to those treated with 
short courses (median time to rejection; 13.5 weeks vs. 7 weeks). 
Sustained allografts for more than 20 weeks were observed in 6 
dogs (29% of evaluable dogs). One of the 2 dogs given DLI 
achieved conversion to full donor chimerism after the third DLI 
dose (CD3+ cells infilsed; lxl07/kg) with subsequent graft versus- 
host disease requiring therapy. Conclusion: Initial engraftment of 
DLA-haploidentical PBSC can be achieved by anti-CD44 therapy 
and 200 cGy TBI with MMF/CSP. In some cases, sustained allo- 
grafts were achieved, however, half the dogs rejected their donor 
grafts after discontinuation or dose-reduction of MMF/CSP. 
Modification to current protocols will be needed to consistently 
achieve long-lasting engraftment. 
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UNRELATED CORD BLOOD TRANSPLANTATION (UCBT) FROM HLA 
DISPARATE DONORS RESULTS IN A VERY LOW RISK OF _>GRADE II 
ACUTE & CHRONIC GVHD: CD34 DOSE AND NON-TBI CONDITIONING 
PREDICT FOR SIGNIFICANTLY IMPROVED SURVIVAL 
Styczy~ski, if/; Billote, G.B.2; Ctse'aJzg, }7; Harrison,, L.:; I, VolozvT~ik, 
K.2; l, Kischhove*, C.2; Ga,z,ilz, ,7.2; B'radley, M.:; Del Toro, G.e; Gemge, 
D.2; ~,an de VeJ~, C.:; Cairo, 3J.S. e 1. AlecLical University Bydgoszcz, 
Bydgoszcz, Poland; 2. ChildreJ~ )Hospital of New York Presbyterian, 
New York, NIT. 
We and others have demonstrated that UCB has been success- 
fully used as an alternative source of hematopoietic stem cells for 
both malignant and non-malignant diseases (Cairo et al, Blood 
90:4665, 1997). We analyzed the results of 31 UCBT in 29 pts 
between 1997-2002. Age: median 9 (0.7-20) yrs; 17M:I2F; and 
reed wt 2i kg" (range 8-95). Dx: 23 malignant (9 ALL, 4 AML, 1 
CML, 3 EID, 3 NHL, 2 NBL, 1 HLH), and 6 non-malignant (1 
B-Thal, 1 WAS, 1 FEL, 1 SAA, 1 FA, 1 Krabbe dis). HLA typing 
was done by serology class i (A & B) and high resolution DNA 
typing class II (DRB1). Donor sources: 3 (6/6), 7 (5/6), 21 (4/6). 
Conditioning: TBI-based (15), chemotherapy-based (6) and 
reduced intensity chemotherapy (10). 28 received ATG/MoAb. 
GVHD prophylaxis: MNIF/FK506 (20), CsA+steroids+~VINiF (7) 
or CsA+Mtx (4). UCB median TNC 4.9x107/kg (1.1-16.9), medi- 
an CD34+ 2.8x105/kg (0.2-9.9). 84% smwived more than 30 days. 
Of those surviving 30 d: med time to ANC >0.5x10~TL 24 d (1- 
79); reed time to PLT >20xl0V/L 31 d (1 206); 81% had ANC 
>0.5xI0')/L by day +60; 67% had PLT ->20x10'TL by day +180. 
There was a 10% primary graft fiailure. 23 were evaluable for 
A/CGVHD. 35% developed _>grade II AGVHD, reed 29d (7-53), 
22% developed ->grade III AGVItD; 5.9% developed extensive 
CGVHD. The estimated 1-yr OS is 42%. 14 remain alive and dis 
free 1-62 mo. Factors predicting positive outcome by univariate 
analysis: number of CD34+ cells/kg (p=0.045), number of 
TNC/kg (p=0.072), non-TBI conditioning (p=0.027), standard 
risk vs poor risk (p-0.036), and sex (F) (p=0.015). By multivariate 
analysis: number of CD34+ cells/kg (p=0.035), non-TBI condi- 
tioning (p=0.026) and sex (F) (p=0.031). Patients who survived 
received more CD34+ eells/kg (3.I vs 2x105, p=0.045) and more 
TNC/kg (5.1 vs 3x107, p=0.11). HLA disparity did not predict for 
OS. In summary, this experience with HLA disparate UCBT con- 
tinues to demonstrate a very low incidence of ->grade II AGVHD 
and extensive CGVHD, and more importantly, in a multivariate 
analysis, non-TBI conditioning and higher CD34/kg dose are the 
most important predictors for significantly improved survival. 
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OPTIMAL SELECTIVE TYPING STRATEGIES FOR DONOR REGISTRIES 
Miiller, C.R. ZKRD Gee'man Ntl. BoTze 3/larrow Donor Regist(y, UlllJ, 
Ge~wla W. 
A reasonable measure for the quality of the composition of a 
registry is the fraction of patients finding at least one matching 
donor on the first search of the registry. This indicates to 
which extent he phenotype spectrum of population is covered 
by the registry. For a population Hardy-Weinberg Equilibri- 
um, this "population coverage" can be estimated using the size 
of the registry and the HLA haplotype frequencies. Due to lim- 
ited funds, many registries contain a majority of donors which 
are only typed for HLA-A and -B. We have designed an algo- 
rithm to select such donors for HLA-DRBl-typing by their 
HLA-A, B-phenotype so that after a defined number of typings 
performed the expected population coverage is maximized. 
This algorithm uses HLA haplotype frequencies to estimate 
absolute HLA-A, B, DR-phenotype frequencies as well as con- 
ditional distributions of HLA-DRB1 subtypes for each HLA-A, 
B-phenotype. Then, taking into account the current registry 
composition, a sequence of donors to be typed for IILA-DRB1 
can be established optimizing the chance of a patient o have an 
HLA-A, B, DRBl-matching donor instantly. A computer sinm- 
lation of this process revealed that our strategy can save initially 
up to 60% of typing costs over a random selection of HLA 
types and that the gain in efficiency will then remain between 
15% and 25% until over 80% of the donors are fully typed. 
Since HLA typing costs are the largest burden on the budget of 
most registries this strategy can have a substantial economic 
impact. 
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OUTCOME OF UNRELATED UMBILICAL CORD-BLOOD TRANSPLANTS 
(UCBT) IN PEDIATRIC PATIENTS: EXPERIENCE OF ONE CENTER 
Rodrigltez-Marino, S. I; Coqldllard, G.~; Scbmoldt, [7.3; Dachao, L. ", 
Racle77zaker, A.z; Kletzel, ~i. s i. Pathology, Childrel~'s Me~lmrial Hospi- 
tal, Chicago, IL; 2. Northzveste*v~ UTdversit~,, Cl, icago, IL; 3. CtailctreJ~'s 
Memorial Hospital Pediatrics, Chicago, IL. 
Unrelated UCBT have been used as an alternative source of 
stem cells in the treatment ofnon-malignant and malignant disor- 
ders. From 7/6/95 to 7/11/02 seventy-one children underwent 
UCBT at Childrens Memorial Hospital. Fifty three had malig- 
nant disorders and 18 non-malignant. Thirty-eight were male and 
33 females with a mean age at transplant of 6.5 years (range 0.6- 
20.5 years). The ablation regimen consisted of fFBI 1200cGy in 
150cGy fractions (days -8, -7, -6, -5), cyclophosphamide 60
mg/kg/day (days -4, -3, -2); and for patients with malignant disor- 
ders VP-16 was given at a lO00mg/m2/day as a CI (day 4). The 
GVHD prophylaxis consisted of CSA 5 mg/kg/day as a 24 hr CI, 
MTX 15/m2 on day 1 and 10rag/m2 on day +3 and +6 plus ATG 
40 lng/kg/day on days +l, +3, +5, and +7. Selection of UCB was 
made based on the HLA typing and total cell dose. HLA typing 
was originally performed by serological methods for class I and by 
DNA based methods for DRB1. Since March 2000, HLA typing 
has been performed using DNA-based typing methods only. 
Eighteen patients were HLA-A, B, and DR typed serologically 
only, and the degree of matching was 6/6 (n= I), 5/6 (n= 6), 4/6 
(n= 10) and 3/6 (n= 1). Fifty-three patients were DNA-typed, 
HLA-A and B at the group level and DRBI at the allele level. In 
these patients the degree of matching was: 6/6 (n=4), 5/6 (n=14), 
4/6 (n=33), and 3/6 (n=2). The total cell dose infused was a mean 
0.63 xl08/kg, (range 0.11- 1.92 xl08/kg). The time to achieve 
ANC> 500/UI were 27.4 (range 14-58 days) was achieved in 58 
pts. And for sustained platelets >20/UI 47days, (range 10-128 
days). And were achieved in 47pts. From the 71 patients, 35 died 
from infection (n= 11), relapse (n= 8), transplant related toxicity 
(n= 3), PTLD (n= 1), chronic GVHD (n= 1), and others (n- 9) 
from these 7 did not engraft. Forty seven patients developed 
AGVIID (grade I/]I n= 32 or grade III/IV n= 15), in 40 of them, 
AGVHD resolved with immune-suppressive th rapy. CGVHD in 
10 patients (resolved in 7, persisted in 3). The actuarial 3-year 
BB&MT lol 
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event free survival was 54%. In conclusion, UCBT is an alterna- 
tive source of hematopoietic stem cells for the treatment of chil- 
dren with malignant and non-malignant diseases who lack a suit- 
able related onor. 
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A-LOCUS MISMATCH DOES NOT ADVERSELY INFLUENCE OUTCOME 
FOLLOWING RELATED-DONOR STEM CELL TRANSPLANTATION (SCT) 
Savoie, M.L.; Sutherland, H.ff.; Hogge, D.E.; Na,tel, S.H.; Toze, C.L.; 
Lavoie, ff.C.; Sheperd, if.D, Song, K.; Forrest, D.; Nevill, T.ff. 
LeukemialB3/iT Progv'am of British Columbia, f~mzcouver, BC, Canada. 
For pts with hematologic diseases requiring SCT who lack a his- 
tocompatible sibling, alternative related-donors (ARD) may be 
considered. Recent evidence suggests that outcome may also 
depend upon the parental source of the mismatched (M/M) haplo- 
type. We reviewed data on 42 pts that underwent ARD-SCT at 
VGH between 01/83 and 05/02:24 males and 18 females with a 
median age of 36 years. Diagnoses included AML (13 pts), CML 
(11 pts), ALL (8 pts) and other (10 pts). Fourteen pts had good 
risk disease. HLA testing was serologic until DNA techniques 
were instituted for class I (02/01) and class II (03/93) typing. 
Donor/recipient were phenotypic matches (PM)(3 pts), one-anti- 
gen M/M (36 pts; A-locus 19 pts, B-locus 6 pts, DR-locus 11 pts) 
or two-antigen M/M. Donors included a sibling (31 pts), a parent 
(8 pts), a child (1 pt) or a first cousin (2 pts). Stem cell source was 
bone marrow in 38 pts, blood in 3 pts or both in 1 pt. Forty pts 
initially engrafted; the remaining 2 pts were rescued with autolo- 
gous (1 pt) or allogeneic (1 pt) blood cells. One pt experienced late 
graft failure requiring a second SCT from the original donor. 
Nine pts died of acute/chronic GVHD, 2 pts from infection and 5 
frmn other causes. Seven pts died of recurrent disease. Nineteen 
pts (45%) remain alive (17 pts in CR, 2 pts in relapse) with a 
median followup of 8.8 (0.3-13.i) years. Pts having had a BMT 
from a one-antigen A-M/M or PM donor (Group 1, n=22) have a 
5 year overall smwival (OAS) of 63 %, treatment related mortality 
(TRM) of 25% and relapse rate (RR) of 16%. For all other pts 
(Group 2) OAS is 19% (p=0.01), TRM is 71% (p=0.01) and RR is 
45% (p=0.05). Incidence of acute GVHD for Group 1 and Group 
2 pts was similar[73% and 65%, respectively (p=0.4)]. There were 
more good-risk pts in Group 1 than in Group 2 (48% vs 20%, 
p=0.10). Five pts received SCT from sibling donors mismatched 
for noninherited maternal antigens (N1MA), 2 of whom are alive 
at 9.8 and 8 years respectively. Two pts received SCT from a sib- 
l ing donor mismatched for noninher i ted paternal antigens 
(NIPA), both of whom have died. ARD-SCT pts that are PM or 
one-antigen A-locu M/M with their donor appear to have out- 
comes similar to that reported for histocompatible siblings. Due 
to low pt nmnbers, the influence of parental donation and the use 
of a sibling with NIMA (rather than N[PA) couldl not be deter- 
mined. 
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THE ABSENCE OF MHC CLASS I ON NEURAL STEM CELLS DOES NOT 
PERMIT NK KILLING AND PREVENTS RECOGNITION BY ALLOREAC- 
TIVE CTL 
l~Iammolenti, 3/I.1; Gajavelli, S.2; Tsozdflts, p.2; Lezg~, R.B.t i. Uniw'r 
sity of 3liami - Microbiology and lnnnu,ology, Miami, FL; 2. Univer- 
sity of Miami - Neurosw'ge'u, Miami, FL. 
Potential applications of neural stem cells (NSC) in syngeneic 
and allogeneic progenitor cell transplantation models requires 
understanding of expression of MHC nmlccules and the ability of 
T cells and NK cells to recognize this progenitor population. 
Cells from the cortices of day 13 embryonic (El3) B6 (I I-2 b) mice 
were explanted and culture(] in serum free N2 media with basic 
fibroblast growth fiactor to select for NSC. Flow cytometric analy- 
sis of cells from P2 through P17 cultures using anti-MHC class 1 
and II mAb showed marginal evels of MI IC H-2K and H-2D 
class I and H-2IA class II expression. However, t itration of 
mr lFN 7 in NSC cultures demonstrated that MHC molecules 
could be strongly upregulated following addition of 3 ng/ml 
mrIFN 7 for 60 hours. To assess the susceptibility of NSC with 
marginal versus high levels of MHC expression to lysis by CTL 
and NK populations, 4 hour 51Cr release assays employing 
untreated and mrlFN 7 treated NSC target cells were performed. 
Results showed that untreated NSC were not recognized by 
BALB/c (H-2 d) allospecific anti-H-2 b CTL, consistent with the 
anti-MHC class I mAb findings. However, upregulation of class I
and II products on both early and later passaged NSC resulted in 
their efficient lysis by CTL. NK  cells were prepared from syn- 
geneic B6 or allogeneic BALB/c mice. Although NK cells effec- 
tively ~lled control YAC-1 target cells, they did not ~11 MHC 
deficient (or expressing) NSC targets. IL 2 augmented NK effec- 
tor ceils also failed to lyse NSC target cells. The findings suggest 
that following transplant of NSC into syngeneic recipients, these 
progenitor cells may not be susceptible to clearance by host NK 
ceils. Their lack of MHC expression may also help to shield such 
cells from immediate host allogeneic T cell recognition. 
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HAPLOIDENTICAL CD34 POSITIVE CELL TRANSPLANTATION IN 
PATIENTS WITH HEMATOLOGICAL MALIGNANCIES 
Tanigztchi, SJ; Ohno, j~ l; J~lineishi, S.:; Kamimzrra, Td; Eamasa- 
ki, S. s; Gondo, Hd; Takaz~e, }22; Harada, M. 1 1. Fukztoka BMT 
Groztp, Fzlk~toka, Japan; 2. Natinal CaTzcer Center Hospital, 
Tok),o, yapa.. 
Much more stem cell sources for allogeneic hematopoietic stem 
ceil transplantation (HST) have been available in this decade such 
as unrelated onors from marrow bank and cord blood bank in 
addition to HLA identical siblings. However, in cases of the 
urgent settings, transplant from haplo-identical related donors is 
the only choice for HST. A multi-center retrospective study is 
conducted to evaluate the feasibility of haplo-identical CD34 pos- 
itive cell transplant from related donors with more than 2 HLA 
loci mismatch. Between 1996 and 2001, a total of 25 patients with 
a variety of hematological malignancy received HST from haplo- 
identical related donors after CD34 positive cell selection. Patient 
mean age was 29 years old ranging from 17 to 69. Two patients 
with ALL/CR1 and 1 MDS (RA) patient were classified as a low 
risk group and 22 as a high risk group with advanced stage which 
is above CRI including 9 cases of second transplantation. All 
patients received positively selected CD34 peripheral blood stem 
cells isolated by CliniMACS (n=15) or Isolex 50 (n=10) system. 
Nineteen patients were conditioned with a conventional TBI con- 
taining regimen and 6 with a reduced-intensity regimen (RIST). 
GVHD prophylaxis were as follows; cyclosporine-based in 18, 
tacrolimus-based in 7 and MMF was added in 3 cases. Primary 
engraftment failure was observed in 6 out of 25 patients. Out of 6 
cases in RIST group, 3 patients were rejected. Later rejection 
after engraftment in day 28 was seen in 1 out of 19 patients evalu 
able. Sepsis with bacterial infection was seen in 9 patients, 2 of 
whom died. Fungal infections occurred in 9 patients, 2 of whom 
died. Regimen-related toxicity (RRT) was also highly observed, 3
patients died of RRT. Three cases died of lethal GVHD and 5 
cases of tumor progression. Eight of 9 second transplant cases 
died within 120 days. The estimated probability of relapse free 
survival (RFS) at 1 year was 23.3 % in all patients, 33.3 % (n=3) 
in the low-risk group and 21.6% in the high risk group (n=22). 
Engraftment failure, infectious disease, RRT and tumor progres- 
sion were the major cause of death. These data indicate that the 
nmre immunosnppressive regimen for engraftment, infection and 
tumor control at transplant are important to obtain better esults. 
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ALTERI~ATIVE DONOR HEMATOPOETIC STEM CELL TRANSPLANTATION 
(HSCT) FOR ACUTE AND CHRONIC LYMPHOID MALIGNANCIES: 20 YEAR 
EXPERIENCE OF THE LEUKEMIA/BMT PROGRAM OF BRITISH COLUMBIA 
%ze, C.; Nevill, T.; Nantel, S.; Fo~west, D.; Shepherd, ft.; Phillips, G.; 
SoJzg, IC; Sntherland, H.; Lavoie, J.; Hogge, D. Leztkemia/BMT Pro- 
gram of British Columbia (Be), DivMon of Hematology, Vancozlver 
Hospital and Health Sdences Cen,'e, BC Ca~zce'r Agem),, and the Uni- 
verdty of British Cbhmzbi,, Vancouver, BC, Canada. 
The role of alternative, unrelated (UD) or HLA mismatched 
related (nunrd) HSC donors for acute and chronic lymphoid 
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